Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15787MR)

This product GTTS-WQ15787MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Hematologic-blood cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15787MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2621MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ7224MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ7768MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GS-5745
GTTS-WQ3360MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-004
GTTS-WQ6943MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ENIA11
GTTS-WQ12842MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ14852MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ7270MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FP3 protein
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW